Based on these findings, Khan and colleagues developed an analogous of the neuropeptide Y (NPY) and, after labeling it with [99mTC], they tested it for imaging of Y1R in four breast cancer patients showing different stages of disease [78]. Here, NPY is linked to breast cancer.